News AstraZeneca PLC Nasdaq

Equities

AZN

US0463531089

Market Closed - Nasdaq Other stock markets 16:15:00 2024-05-03 EDT			5-day change	1st Jan Change
76.35 ^USD	+0.73%		+1.57%	+13.36%

05-03	Angle shares up on assay development deal with AstraZeneca	AN
05-03	Angle shares up on assay development deal with AstraZenaca	AN

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Combination treatment could provide new standard-of-care for aggressive lymphoma	05-03	AQ
AI Startup Fileread Names Former AstraZeneca Legal Leader as Chief Strategy Officer and General Counsel to Drive Product Development and Accelerate Growth	05-03	AQ
Angle shares up on assay development deal with AstraZeneca	05-03	AN
Astrazeneca - CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	05-03	AQ
Angle shares up on assay development deal with AstraZenaca	05-03	AN
Angle Plc to Supply Prostate Cancer Androgen Receptor Detection Assay to AstraZeneca	05-03	MT
AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal	05-03	AN
Confident start before US jobs data	05-03	AN
InterContinental Hotels makes first-quarter progress	05-03	AN
AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial	05-02	MT
AstraZeneca: research into respiratory diseases	05-02	CF
AstraZeneca : Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial - Form 6-K	05-02	PU
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	05-02	BU
AstraZeneca Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial	05-02	CI
AstraZeneca PLC Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial	05-02	CI
AstraZeneca: encouraging results in lymphoma	05-02	CF
AstraZeneca notes positive trial results for Calquence treatment	05-02	AN
AstraZeneca's Blood Cancer Combo Extends Progression-free Survival in Late-stage Study	05-02	MT
Ipsen: new President for North America	05-02	CF
AstraZeneca PLC Announces Calquence combination improved PFS in 1L MCL	05-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm